A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML) Clinical Trial

Official title:
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Preliminary Efficacy of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Status Recruiting

Clinical Trial Summary

NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hematologic Neoplasms
Leukemia, Myeloid, Acute
Relapsed/Refractory Acute Myeloid Leukemia (AML)

Clinical Trial Details

NCT number	NCT06049667
Study type	Interventional
Source	Nanjing Chia-tai Tianqing Pharmaceutical
Contact	Yu meng Zhou
Phone	86-025-85109999
Email	yumeng_zhou@163.com
Status	Recruiting
Phase	Phase 1
Start date	August 7, 2023
Completion date	August 2026

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03541369` - Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT05143996` - CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	Phase 1
Completed	`NCT02626338` - Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML	Phase 1/Phase 2
Not yet recruiting	`NCT05662904` - Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML	Phase 1